Xilio Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
Xilio Therapeutics, Inc. (XLO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2023-03-02
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-12-31 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-09-30 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-06-30 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-03-31 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2022 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2021 was $0.00.
- Xilio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2020 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 derived: sum of 4 quarters · filed 2023-03-02 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |